a medical imaging company specializing in advanced
optical coherence tomography (OCT) technology, has announced the
appointment of Miguel Eslava to the new position of vice president and
chief operating officer. With more than a decade of senior management
experience at GE Healthcare, Mr. Eslava brings significant business
operations expertise to the company in advance of the anticipated launch
of the first point-of-care diagnostic imaging system for dermatology in
the second half of 2014.
"We expect Miguel to play a critical role at MedLumics as we move from a
research and development stage company to a commercial organization,"
said Eduardo Margallo, president and co-founder of MedLumics. "His
knowledge and experience will be invaluable as we build the
infrastructure to support the launch of our first diagnostic imaging
system for dermatology."
During his 12-year tenure at GE Healthcare, Mr. Eslava held senior
management positions at both a national and international level. Most
recently, he was president of GE Healthcare Spain and Portugal, a group
including GE Medical Systems S.A., GE Medical Systems Information
Technology S.A., Datex Ohmeda S.L., Amersham Health S.A. and Amersham
Health Radiofarmacos S.L. He previously served as general sales manager
for GE Medical Systems Spain and Portugal, and held other
responsibilities within the GE group, including general services manager
for GE Medical Systems, vice president & COO for GE Capital ITS Spain,
and general manager for GE Clinical Services in the EMEA region.
MedLumics has developed OCT imaging technology that integrates all
optical and electrical components in a compact microchip-based system
that can produce dynamic, real-time, high-resolution diagnostic images
with a tissue penetration capability of up to two millimeters. The
proprietary technology is designed to allow for ultra-portable devices
and to give physicians a complementary diagnostic imaging system that
will enable patient treatment at the point of care.
The company's first hand-held device, expected to launch in the second
half of 2014, will help dermatologists to quickly and minimally
invasively diagnose skin cancer, among other pathologies. The device
combines epiluminescent microscopy and OCT imagery in a patent-protected
built-in display that integrates seamlessly with current
patient-centered workflows. Additionally, MedLumics' solution provides
the clinician with novel real-time information to guide and monitor the
non-invasive treatment of skin cancer using topical or light-activated
"We believe our proprietary platform technology has the potential to
transform the field of diagnostics and therapy guidance across a number
of clinical segments, including dermatology, where we will initially
focus," Mr. Margallo said. "Our first product offering combines a
tested, real-world technology that provides basic surface information
with an advanced sectional imaging modality that was up to now only
available in research-oriented systems. This results in a compact,
easy-to-use system that gives physicians the ability to perform rapid
and advanced diagnostics at the point of care and, as a result, to
provide better therapies to their patients."
The company is further actively developing its miniaturized integrated
optics technology for catheter-based applications, including an
optically guided radiofrequency (RF) ablation system for managing
Founded in 2009, MedLumics is a medical imaging company specializing in
advanced optical coherence tomography (OCT) devices. Its proprietary
integrated optics platform technology combines optical and electrical
components in a miniature package, enabling for the first time
ultra-portable, hand-held OCT systems that produce high quality
real-time images. The systems allow physicians to improve diagnostic and
therapeutic procedures through a non-invasive optical evaluation of
tissue. MedLumics received a 3.5 million Euro/4.7 million USD Series A
financing from joint investors Ysios Capital Partners and "la Caixa"
(through Caixa Capital Risc) in November 2011.
For more information, visit www.medlumics.com
[ Back To NFVZone's Homepage ]